文献速递复苏、休克与脓毒症心脑血管急症

兰地洛尔治疗院外心脏骤停难治性心室颤动:一项随机、双盲、安慰剂对照先导试验

Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial.
PubMed 文献 · Resuscitation · 2024-06-10
一句话结论对肾上腺素和胺碘酮预处理后的院外心脏骤停难治性室颤患者,加用兰地洛尔20 mg团注未缩短持续自主循环恢复时间,且可能与心动过缓和无收缩相关。

这项随机、双盲、安慰剂对照先导试验纳入36例院外心脏骤停合并复发或难治性室颤(至少3次除颤且最后一次心律可电击)且已接受肾上腺素和胺碘酮预处理的患者,分别接受兰地洛尔20 mg团注(19例)或安慰剂(17例)。从试验药物输注到持续自主循环恢复的时间两组相似(兰地洛尔组39分钟 vs 安慰剂组41分钟)。兰地洛尔组持续自主循环恢复比例数值上低于安慰剂组(7例[36.8%] vs 11例[64.7%])。兰地洛尔组在试验药物输注后15分钟内发生无收缩显著多于安慰剂组(7例[36.8%] vs 0例[0.0%])。作者认为兰地洛尔可能与心动过缓和无收缩相关。

要点

  • 对肾上腺素和胺碘酮预处理后的院外心脏骤停难治性室颤患者,加用兰地洛尔20 mg团注未缩短持续自主循环恢复时间(兰地洛尔组39分钟 vs 安慰剂组41分钟)。
  • 兰地洛尔组持续自主循环恢复比例数值上低于安慰剂组(7例[36.8%] vs 11例[64.7%])。
  • 兰地洛尔组试验药物输注后15分钟内无收缩发生显著多于安慰剂组(7例[36.8%] vs 0例[0.0%])。
  • 作者认为兰地洛尔可能与心动过缓和无收缩相关。

适用人群与场景

  • 院外心脏骤停合并复发或难治性室颤、至少3次除颤且最后一次心律可电击、已接受肾上腺素和胺碘酮预处理的患者。

诊断标准与关键阈值

  • 难治性室颤定义为至少3次除颤尝试且最后一次心律为可电击心律。

处置流程与药物剂量

  • 在肾上腺素和胺碘酮预处理基础上,加用兰地洛尔20 mg团注输注或安慰剂。

红旗征与不能漏的情况

  • 兰地洛尔组试验药物输注后15分钟内无收缩发生显著多于安慰剂组(7例[36.8%] vs 0例[0.0%])。

研究设计与关键结果

  • 随机、双盲、安慰剂对照先导试验,共纳入36例患者,兰地洛尔组19例、安慰剂组17例。
  • 主要疗效终点从试验药物输注到持续自主循环恢复的时间两组相似:兰地洛尔组39分钟 vs 安慰剂组41分钟。
  • 持续自主循环恢复兰地洛尔组7例(36.8%)vs 安慰剂组11例(64.7%)。
  • 试验药物输注后15分钟内无收缩兰地洛尔组7例(36.8%)vs 安慰剂组0例(0.0%),兰地洛尔组显著更多。
  • 安全性结局包括心动过缓和无收缩的发生。

证据类型、等级与局限

  • 随机、双盲、安慰剂对照先导试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对肾上腺素和胺碘酮预处理后的院外心脏骤停难治性室颤患者,加用兰地洛尔20 mg团注未缩短持续自主循环恢复时间。
  • 作者认为兰地洛尔可能与心动过缓和无收缩相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Out-of-hospital cardiac arrest (OHCA) complicated by refractory ventricular fibrillation (VF) is associated with poor outcome. Beta-1-receptor selective blockade might overcome refractory VF and improve survival. This trial investigates the efficacy and safety of prehospital landiolol in OHCA and refractory VF.

METHODS: In this randomized, double-blind, placebo-controlled pilot trial, patients with OHCA and recurrent or refractory VF (at least 3 defibrillation attempts and last rhythm shockable), pretreated with epinephrine and amiodarone, were allocated to receive add-on treatment with landiolol or placebo. Landiolol was given as a 20 mg bolus infusion. The primary efficacy outcome was time from trial drug infusion to sustained return of spontaneous circulation (ROSC). Safety outcomes included the onset of bradycardia and asystole.

RESULTS: A total of 36 patients were enrolled, 19 were allocated to the landiolol group and 17 to the placebo group. Time from trial drug infusion to sustained ROSC was similar between treatment groups (39 min [landiolol] versus 41 min [placebo]). Sustained ROSC was numerically lower in the landiolol group compared with the placebo group (7 patients [36.8%] versus 11 patients [64.7%], respectively). Asystole within 15 min of trial drug infusion occurred significantly more often in the landiolol group than in the placebo group (7 patients [36.8%] and 0 patients [0.0%], respectively).

CONCLUSION: In patients with OHCA and refractory VF who are pretreated with epinephrine and amiodarone, add-on bolus infusion of landiolol 20 mg did not lead to a shorter time to sustained ROSC compared with placebo. Landiolol might be associated with bradycardia and asystole.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Gelbenegger G, Jilma B, Horvath LC, et al. Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial. Resuscitation. 2024. PMID: 38866231. doi:10.1016/j.resuscitation.2024.110273

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。